Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?

Ryan Sun¹, Lee-Jen Wei²

Affiliations

¹ Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston.
² Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

PMID: 38329744
DOI: 10.1001/jamaoncol.2023.6957

Comment

Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?

Ryan Sun et al. JAMA Oncol. 2024.

. 2024 Apr 1;10(4):537.

doi: 10.1001/jamaoncol.2023.6957.

Authors

Ryan Sun¹, Lee-Jen Wei²

Affiliations

¹ Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston.
² Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

PMID: 38329744
DOI: 10.1001/jamaoncol.2023.6957

No abstract available

PubMed Disclaimer

Comment in

Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply.
Huober J, Thürlimann B, Dietrich D. Huober J, et al. JAMA Oncol. 2024 Apr 1;10(4):537-538. doi: 10.1001/jamaoncol.2023.6960. JAMA Oncol. 2024. PMID: 38329767 No abstract available.

Comment on

Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H; Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Huober J, et al. JAMA Oncol. 2023 Oct 1;9(10):1381-1389. doi: 10.1001/jamaoncol.2023.2909. JAMA Oncol. 2023. PMID: 37561451 Free PMC article. Clinical Trial.

References

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?

Affiliations

Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?

Authors

Affiliations

Comment in

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous